51. High plasma levels of soluble Fas in HIV type 1-infected subjects are not normalized during highly active antiretroviral therapy
- Author
-
Maurizio Zazzi, Bo Hejdeman, Francesca Chiodi, Angelo De Milito, Jan Albert, Anders Sönnerborg, and Soo Aleman
- Subjects
Time Factors ,Anti-HIV Agents ,Matched-Pair Analysis ,medicine.medical_treatment ,Immunology ,HIV Infections ,Viremia ,Virus Replication ,Fas ligand ,Antiretroviral Therapy, Highly Active ,Virology ,Immunopathology ,Blood plasma ,Humans ,Medicine ,Longitudinal Studies ,fas Receptor ,Sida ,Retrospective Studies ,Chemotherapy ,biology ,business.industry ,virus diseases ,biology.organism_classification ,medicine.disease ,CD4 Lymphocyte Count ,Cross-Sectional Studies ,Infectious Diseases ,Lentivirus ,HIV-1 ,RNA, Viral ,Reverse Transcriptase Inhibitors ,Viral disease ,business - Abstract
Plasma levels of soluble Fas (sFas) are elevated in human immunodeficiency virus type 1 (HIV-1) infection, indicating dysregulation of the Fas apoptosis pathway and chronic immune activation. We performed a retrospective study to investigate the effects of HAART on plasma levels of sFas. A cross-sectional study of 27 drug-naive infected subjects and 49 patients under antiretroviral treatment showed that plasma levels of sFas were higher in HIV-1-infected subjects than in 52 HIV-1-negative controls, independently of the treatment status. In a longitudinal study of 69 patients undergoing HAART, we observed a minimal, but significant decrease in sFas plasma levels after 1 year of therapy. Levels of sFas, however, remained still higher than physiologic values. Patients undergoing HAART were further classified as nonresponders or responders on the basis of viremia suppression; no significant changes in plasma levels of sFas were observed between the two groups. These findings show that 1 year of HAART has a minor effect on the sFas levels in plasma. Long-term HAART may be required to normalize the dysregulation of the Fas apoptotic pathway and the persistent immune activation initiated by HIV-1.